Fig. 6From: New frontiers in immune checkpoint B7-H3 (CD276) research and drug developmentCancer immunotherapeutic approaches targeting B7-H3. Anti-B7-H3 approaches using different mechanisms including monoclonal antibodies (mAbs), antibody-dependent cell mediated cytotoxicity (ADCC), CAR-T therapy, and Antibody Drug Conjugate (ADC) have been exploredBack to article page